Xiagem 1 Tablet PR contains a combination of Glimepiride 1 mg and Metformin 500 mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. This combination provides complementary mechanisms of action, offering effective control of blood glucose levels in patients inadequately managed by diet and exercise alone. Xiagem 1 Tablet PR is indicated for adult patients with type 2 diabetes who require dual therapy to achieve glycemic targets. The prolonged-release formulation ensures a steady release of active ingredients, promoting better compliance and minimizing fluctuations in plasma drug concentrations. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and contraindications include severe renal dysfunction, metabolic acidosis, and known hypersensitivity to either component. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare lactic acidosis. Xiagem 1 Tablet PR should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring.